ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Anti-inflammatory and Antipyretic Granules Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-32S17429
Home | Market Reports | Health| Pharmacy
Global Anti inflammatory and Antipyretic Granules Market Research Report 2024
BUY CHAPTERS

Global Anti-inflammatory and Antipyretic Granules Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-32S17429
Report
October 2025
Pages:180
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sichuan Kelun Pharmaceutical Co., Ltd.
Yunnan Baiyao Group Co., Ltd
Dong'e Ejiao Co., Ltd.
Jilin Xianfeng Technology Pharmaceutical Co., Ltd.
Sichuan Luye Pharmaceutical Co., Ltd.
Yunnan Longfa Pharmaceutical Co., Ltd.
Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.
Hebei Tiancheng Pharmaceutical Co., Ltd
Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.
Hubei Dongxin Pharmaceutical Co., Ltd.
Hubei Nordeson Pharmaceutical Co., Ltd.
Shaanxi Han Tang Pharmaceutical Co., Ltd.
Liaoning Xingao Pharmaceutical Co., Ltd.

Anti-inflammatory and Antipyretic Granules Market

The global Anti-inflammatory and Antipyretic Granules market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Online Sales accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Anti-inflammatory and Antipyretic Granules leading manufacturers including Guangdong Baihe Pharmaceutical Co., Ltd., Shenyang Junyuan Pharmaceutical Co., Ltd., Guangxi Tiantianle Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd., Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd., Yunnan Baiyao Group Co., Ltd., Hubei Dongxin Pharmaceutical Co., Ltd., Dong'e Ejiao Co., Ltd., Jilin Xianfeng Technology Pharmaceutical Co., Ltd., etc., dominate supply; the top five capture approximately % of global revenue, with Guangdong Baihe Pharmaceutical Co., Ltd. leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Anti-inflammatory and Antipyretic Granules market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Anti-inflammatory and Antipyretic Granules Market Report

Report Metric Details
Report Name Anti-inflammatory and Antipyretic Granules Market
Segment by Type
  • Pack of 10
  • Pack of 16
Segment by Application
  • Online Sales
  • Offline Sales
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Guangdong Baihe Pharmaceutical Co., Ltd., Shenyang Junyuan Pharmaceutical Co., Ltd., Guangxi Tiantianle Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd., Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd., Yunnan Baiyao Group Co., Ltd., Hubei Dongxin Pharmaceutical Co., Ltd., Dong'e Ejiao Co., Ltd., Jilin Xianfeng Technology Pharmaceutical Co., Ltd., Hubei Nordeson Pharmaceutical Co., Ltd., Sichuan Luye Pharmaceutical Co., Ltd., Yunnan Longfa Pharmaceutical Co., Ltd., Shaanxi Han Tang Pharmaceutical Co., Ltd., Jiangxi Jimin Kexin Pharmaceutical Co., Ltd., Liaoning Xingao Pharmaceutical Co., Ltd., Hebei Tiancheng Pharmaceutical Co., Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Anti-inflammatory and Antipyretic Granules study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Anti-inflammatory and Antipyretic Granules Market report?

Ans: The main players in the Anti-inflammatory and Antipyretic Granules Market are Guangdong Baihe Pharmaceutical Co., Ltd., Shenyang Junyuan Pharmaceutical Co., Ltd., Guangxi Tiantianle Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Shaanxi Buchang Pharmaceutical Co., Ltd., Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd., Yunnan Baiyao Group Co., Ltd., Hubei Dongxin Pharmaceutical Co., Ltd., Dong'e Ejiao Co., Ltd., Jilin Xianfeng Technology Pharmaceutical Co., Ltd., Hubei Nordeson Pharmaceutical Co., Ltd., Sichuan Luye Pharmaceutical Co., Ltd., Yunnan Longfa Pharmaceutical Co., Ltd., Shaanxi Han Tang Pharmaceutical Co., Ltd., Jiangxi Jimin Kexin Pharmaceutical Co., Ltd., Liaoning Xingao Pharmaceutical Co., Ltd., Hebei Tiancheng Pharmaceutical Co., Ltd.

What are the Application segmentation covered in the Anti-inflammatory and Antipyretic Granules Market report?

Ans: The Applications covered in the Anti-inflammatory and Antipyretic Granules Market report are Online Sales, Offline Sales

What are the Type segmentation covered in the Anti-inflammatory and Antipyretic Granules Market report?

Ans: The Types covered in the Anti-inflammatory and Antipyretic Granules Market report are Pack of 10, Pack of 16

1 Study Coverage
1.1 Introduction to Anti-inflammatory and Antipyretic Granules: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Anti-inflammatory and Antipyretic Granules Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Pack of 10
1.2.3 Pack of 16
1.3 Market Segmentation by Application
1.3.1 Global Anti-inflammatory and Antipyretic Granules Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Online Sales
1.3.3 Offline Sales
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-inflammatory and Antipyretic Granules Revenue Estimates and Forecasts 2020-2031
2.2 Global Anti-inflammatory and Antipyretic Granules Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Anti-inflammatory and Antipyretic Granules Sales Estimates and Forecasts 2020-2031
2.4 Global Anti-inflammatory and Antipyretic Granules Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Anti-inflammatory and Antipyretic Granules Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Anti-inflammatory and Antipyretic Granules Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Pack of 10 Market Size by Manufacturers
3.5.2 Pack of 16 Market Size by Manufacturers
3.6 Global Anti-inflammatory and Antipyretic Granules Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Anti-inflammatory and Antipyretic Granules Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Anti-inflammatory and Antipyretic Granules Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Anti-inflammatory and Antipyretic Granules Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Anti-inflammatory and Antipyretic Granules Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Anti-inflammatory and Antipyretic Granules Sales and Revenue by Type (2020-2031)
6.4 North America Anti-inflammatory and Antipyretic Granules Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Anti-inflammatory and Antipyretic Granules Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Anti-inflammatory and Antipyretic Granules Sales and Revenue by Type (2020-2031)
7.4 Europe Anti-inflammatory and Antipyretic Granules Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Anti-inflammatory and Antipyretic Granules Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Anti-inflammatory and Antipyretic Granules Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Anti-inflammatory and Antipyretic Granules Sales and Revenue by Type (2020-2031)
9.4 Central and South America Anti-inflammatory and Antipyretic Granules Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Anti-inflammatory and Antipyretic Granules Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Anti-inflammatory and Antipyretic Granules Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Anti-inflammatory and Antipyretic Granules Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Anti-inflammatory and Antipyretic Granules Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Guangdong Baihe Pharmaceutical Co., Ltd.
11.1.1 Guangdong Baihe Pharmaceutical Co., Ltd. Corporation Information
11.1.2 Guangdong Baihe Pharmaceutical Co., Ltd. Business Overview
11.1.3 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.1.4 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Product in 2024
11.1.6 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Application in 2024
11.1.7 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Geographic Area in 2024
11.1.8 Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
11.1.9 Guangdong Baihe Pharmaceutical Co., Ltd. Recent Developments
11.2 Shenyang Junyuan Pharmaceutical Co., Ltd.
11.2.1 Shenyang Junyuan Pharmaceutical Co., Ltd. Corporation Information
11.2.2 Shenyang Junyuan Pharmaceutical Co., Ltd. Business Overview
11.2.3 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.2.4 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Product in 2024
11.2.6 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Application in 2024
11.2.7 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Geographic Area in 2024
11.2.8 Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
11.2.9 Shenyang Junyuan Pharmaceutical Co., Ltd. Recent Developments
11.3 Guangxi Tiantianle Pharmaceutical Co., Ltd.
11.3.1 Guangxi Tiantianle Pharmaceutical Co., Ltd. Corporation Information
11.3.2 Guangxi Tiantianle Pharmaceutical Co., Ltd. Business Overview
11.3.3 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.3.4 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Product in 2024
11.3.6 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Application in 2024
11.3.7 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Geographic Area in 2024
11.3.8 Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
11.3.9 Guangxi Tiantianle Pharmaceutical Co., Ltd. Recent Developments
11.4 Sichuan Kelun Pharmaceutical Co., Ltd.
11.4.1 Sichuan Kelun Pharmaceutical Co., Ltd. Corporation Information
11.4.2 Sichuan Kelun Pharmaceutical Co., Ltd. Business Overview
11.4.3 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.4.4 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Product in 2024
11.4.6 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Application in 2024
11.4.7 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Geographic Area in 2024
11.4.8 Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
11.4.9 Sichuan Kelun Pharmaceutical Co., Ltd. Recent Developments
11.5 Shaanxi Buchang Pharmaceutical Co., Ltd.
11.5.1 Shaanxi Buchang Pharmaceutical Co., Ltd. Corporation Information
11.5.2 Shaanxi Buchang Pharmaceutical Co., Ltd. Business Overview
11.5.3 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.5.4 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Product in 2024
11.5.6 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Application in 2024
11.5.7 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales by Geographic Area in 2024
11.5.8 Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
11.5.9 Shaanxi Buchang Pharmaceutical Co., Ltd. Recent Developments
11.6 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.
11.6.1 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Corporation Information
11.6.2 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Business Overview
11.6.3 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.6.4 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Recent Developments
11.7 Yunnan Baiyao Group Co., Ltd.
11.7.1 Yunnan Baiyao Group Co., Ltd. Corporation Information
11.7.2 Yunnan Baiyao Group Co., Ltd. Business Overview
11.7.3 Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.7.4 Yunnan Baiyao Group Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Yunnan Baiyao Group Co., Ltd. Recent Developments
11.8 Hubei Dongxin Pharmaceutical Co., Ltd.
11.8.1 Hubei Dongxin Pharmaceutical Co., Ltd. Corporation Information
11.8.2 Hubei Dongxin Pharmaceutical Co., Ltd. Business Overview
11.8.3 Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.8.4 Hubei Dongxin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Hubei Dongxin Pharmaceutical Co., Ltd. Recent Developments
11.9 Dong'e Ejiao Co., Ltd.
11.9.1 Dong'e Ejiao Co., Ltd. Corporation Information
11.9.2 Dong'e Ejiao Co., Ltd. Business Overview
11.9.3 Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.9.4 Dong'e Ejiao Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Dong'e Ejiao Co., Ltd. Recent Developments
11.10 Jilin Xianfeng Technology Pharmaceutical Co., Ltd.
11.10.1 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Corporation Information
11.10.2 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Business Overview
11.10.3 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.10.4 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Recent Developments
11.11 Hubei Nordeson Pharmaceutical Co., Ltd.
11.11.1 Hubei Nordeson Pharmaceutical Co., Ltd. Corporation Information
11.11.2 Hubei Nordeson Pharmaceutical Co., Ltd. Business Overview
11.11.3 Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.11.4 Hubei Nordeson Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Hubei Nordeson Pharmaceutical Co., Ltd. Recent Developments
11.12 Sichuan Luye Pharmaceutical Co., Ltd.
11.12.1 Sichuan Luye Pharmaceutical Co., Ltd. Corporation Information
11.12.2 Sichuan Luye Pharmaceutical Co., Ltd. Business Overview
11.12.3 Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.12.4 Sichuan Luye Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Sichuan Luye Pharmaceutical Co., Ltd. Recent Developments
11.13 Yunnan Longfa Pharmaceutical Co., Ltd.
11.13.1 Yunnan Longfa Pharmaceutical Co., Ltd. Corporation Information
11.13.2 Yunnan Longfa Pharmaceutical Co., Ltd. Business Overview
11.13.3 Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.13.4 Yunnan Longfa Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Yunnan Longfa Pharmaceutical Co., Ltd. Recent Developments
11.14 Shaanxi Han Tang Pharmaceutical Co., Ltd.
11.14.1 Shaanxi Han Tang Pharmaceutical Co., Ltd. Corporation Information
11.14.2 Shaanxi Han Tang Pharmaceutical Co., Ltd. Business Overview
11.14.3 Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.14.4 Shaanxi Han Tang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Shaanxi Han Tang Pharmaceutical Co., Ltd. Recent Developments
11.15 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.
11.15.1 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Corporation Information
11.15.2 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Business Overview
11.15.3 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.15.4 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Recent Developments
11.16 Liaoning Xingao Pharmaceutical Co., Ltd.
11.16.1 Liaoning Xingao Pharmaceutical Co., Ltd. Corporation Information
11.16.2 Liaoning Xingao Pharmaceutical Co., Ltd. Business Overview
11.16.3 Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.16.4 Liaoning Xingao Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Liaoning Xingao Pharmaceutical Co., Ltd. Recent Developments
11.17 Hebei Tiancheng Pharmaceutical Co., Ltd.
11.17.1 Hebei Tiancheng Pharmaceutical Co., Ltd. Corporation Information
11.17.2 Hebei Tiancheng Pharmaceutical Co., Ltd. Business Overview
11.17.3 Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Product Models, Descriptions and Specifications
11.17.4 Hebei Tiancheng Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Hebei Tiancheng Pharmaceutical Co., Ltd. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Anti-inflammatory and Antipyretic Granules Industry Chain
12.2 Anti-inflammatory and Antipyretic Granules Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Anti-inflammatory and Antipyretic Granules Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Anti-inflammatory and Antipyretic Granules Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Anti-inflammatory and Antipyretic Granules Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Anti-inflammatory and Antipyretic Granules Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Sichuan Kelun Pharmaceutical Co., Ltd.
Yunnan Baiyao Group Co., Ltd
Dong'e Ejiao Co., Ltd.
Jilin Xianfeng Technology Pharmaceutical Co., Ltd.
Sichuan Luye Pharmaceutical Co., Ltd.
Yunnan Longfa Pharmaceutical Co., Ltd.
Jiangxi Jimin Kexin Pharmaceutical Co., Ltd.
Hebei Tiancheng Pharmaceutical Co., Ltd
Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd.
Hubei Dongxin Pharmaceutical Co., Ltd.
Hubei Nordeson Pharmaceutical Co., Ltd.
Shaanxi Han Tang Pharmaceutical Co., Ltd.
Liaoning Xingao Pharmaceutical Co., Ltd.
List of Tables
 Table 1. Global Anti-inflammatory and Antipyretic Granules Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Anti-inflammatory and Antipyretic Granules Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Anti-inflammatory and Antipyretic Granules Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Anti-inflammatory and Antipyretic Granules Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Anti-inflammatory and Antipyretic Granules Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Anti-inflammatory and Antipyretic Granules Sales by Region (2020-2025) & (K Units)
 Table 8. Global Anti-inflammatory and Antipyretic Granules Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Anti-inflammatory and Antipyretic Granules Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Anti-inflammatory and Antipyretic Granules Sales Share by Manufacturers (2020-2025)
 Table 12. Global Anti-inflammatory and Antipyretic Granules Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Anti-inflammatory and Antipyretic Granules Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Anti-inflammatory and Antipyretic Granules by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-inflammatory and Antipyretic Granules as of 2024)
 Table 16. Global Anti-inflammatory and Antipyretic Granules Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Anti-inflammatory and Antipyretic Granules Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Anti-inflammatory and Antipyretic Granules Manufacturing Base and Headquarters
 Table 19. Global Anti-inflammatory and Antipyretic Granules Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Anti-inflammatory and Antipyretic Granules Sales by Type (2020-2025) & (K Units)
 Table 23. Global Anti-inflammatory and Antipyretic Granules Sales by Type (2026-2031) & (K Units)
 Table 24. Global Anti-inflammatory and Antipyretic Granules Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Anti-inflammatory and Antipyretic Granules Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Anti-inflammatory and Antipyretic Granules ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Anti-inflammatory and Antipyretic Granules Sales by Application (2020-2025) & (K Units)
 Table 29. Global Anti-inflammatory and Antipyretic Granules Sales by Application (2026-2031) & (K Units)
 Table 30. Anti-inflammatory and Antipyretic Granules High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Anti-inflammatory and Antipyretic Granules Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Anti-inflammatory and Antipyretic Granules Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Anti-inflammatory and Antipyretic Granules ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Anti-inflammatory and Antipyretic Granules Growth Accelerators and Market Barriers
 Table 37. North America Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Anti-inflammatory and Antipyretic Granules Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Anti-inflammatory and Antipyretic Granules Growth Accelerators and Market Barriers
 Table 40. Europe Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Anti-inflammatory and Antipyretic Granules Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Anti-inflammatory and Antipyretic Granules Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Anti-inflammatory and Antipyretic Granules Investment Opportunities and Key Challenges
 Table 47. Central and South America Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Anti-inflammatory and Antipyretic Granules Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Anti-inflammatory and Antipyretic Granules Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Guangdong Baihe Pharmaceutical Co., Ltd. Corporation Information
 Table 51. Guangdong Baihe Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 52. Guangdong Baihe Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 53. Guangdong Baihe Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Guangdong Baihe Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
 Table 55. Guangdong Baihe Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
 Table 56. Guangdong Baihe Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 57. Guangdong Baihe Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
 Table 58. Guangdong Baihe Pharmaceutical Co., Ltd. Recent Developments
 Table 59. Shenyang Junyuan Pharmaceutical Co., Ltd. Corporation Information
 Table 60. Shenyang Junyuan Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 61. Shenyang Junyuan Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 62. Shenyang Junyuan Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Shenyang Junyuan Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
 Table 64. Shenyang Junyuan Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
 Table 65. Shenyang Junyuan Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 66. Shenyang Junyuan Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
 Table 67. Shenyang Junyuan Pharmaceutical Co., Ltd. Recent Developments
 Table 68. Guangxi Tiantianle Pharmaceutical Co., Ltd. Corporation Information
 Table 69. Guangxi Tiantianle Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 70. Guangxi Tiantianle Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 71. Guangxi Tiantianle Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Guangxi Tiantianle Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
 Table 73. Guangxi Tiantianle Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
 Table 74. Guangxi Tiantianle Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 75. Guangxi Tiantianle Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
 Table 76. Guangxi Tiantianle Pharmaceutical Co., Ltd. Recent Developments
 Table 77. Sichuan Kelun Pharmaceutical Co., Ltd. Corporation Information
 Table 78. Sichuan Kelun Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 79. Sichuan Kelun Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 80. Sichuan Kelun Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Sichuan Kelun Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
 Table 82. Sichuan Kelun Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
 Table 83. Sichuan Kelun Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 84. Sichuan Kelun Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
 Table 85. Sichuan Kelun Pharmaceutical Co., Ltd. Recent Developments
 Table 86. Shaanxi Buchang Pharmaceutical Co., Ltd. Corporation Information
 Table 87. Shaanxi Buchang Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 88. Shaanxi Buchang Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 89. Shaanxi Buchang Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Shaanxi Buchang Pharmaceutical Co., Ltd. Sales Value Proportion by Product in 2024
 Table 91. Shaanxi Buchang Pharmaceutical Co., Ltd. Sales Value Proportion by Application in 2024
 Table 92. Shaanxi Buchang Pharmaceutical Co., Ltd. Sales Value Proportion by Geographic Area in 2024
 Table 93. Shaanxi Buchang Pharmaceutical Co., Ltd. Anti-inflammatory and Antipyretic Granules SWOT Analysis
 Table 94. Shaanxi Buchang Pharmaceutical Co., Ltd. Recent Developments
 Table 95. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Corporation Information
 Table 96. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 97. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 98. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. Nanning Kangnuo Biochemical Pharmaceutical Co., Ltd. Recent Developments
 Table 100. Yunnan Baiyao Group Co., Ltd. Corporation Information
 Table 101. Yunnan Baiyao Group Co., Ltd. Description and Major Businesses
 Table 102. Yunnan Baiyao Group Co., Ltd. Product Models, Descriptions and Specifications
 Table 103. Yunnan Baiyao Group Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. Yunnan Baiyao Group Co., Ltd. Recent Developments
 Table 105. Hubei Dongxin Pharmaceutical Co., Ltd. Corporation Information
 Table 106. Hubei Dongxin Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 107. Hubei Dongxin Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 108. Hubei Dongxin Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Hubei Dongxin Pharmaceutical Co., Ltd. Recent Developments
 Table 110. Dong'e Ejiao Co., Ltd. Corporation Information
 Table 111. Dong'e Ejiao Co., Ltd. Description and Major Businesses
 Table 112. Dong'e Ejiao Co., Ltd. Product Models, Descriptions and Specifications
 Table 113. Dong'e Ejiao Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Dong'e Ejiao Co., Ltd. Recent Developments
 Table 115. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Corporation Information
 Table 116. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 117. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 118. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 119. Jilin Xianfeng Technology Pharmaceutical Co., Ltd. Recent Developments
 Table 120. Hubei Nordeson Pharmaceutical Co., Ltd. Corporation Information
 Table 121. Hubei Nordeson Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 122. Hubei Nordeson Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 123. Hubei Nordeson Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 124. Hubei Nordeson Pharmaceutical Co., Ltd. Recent Developments
 Table 125. Sichuan Luye Pharmaceutical Co., Ltd. Corporation Information
 Table 126. Sichuan Luye Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 127. Sichuan Luye Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 128. Sichuan Luye Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 129. Sichuan Luye Pharmaceutical Co., Ltd. Recent Developments
 Table 130. Yunnan Longfa Pharmaceutical Co., Ltd. Corporation Information
 Table 131. Yunnan Longfa Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 132. Yunnan Longfa Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 133. Yunnan Longfa Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 134. Yunnan Longfa Pharmaceutical Co., Ltd. Recent Developments
 Table 135. Shaanxi Han Tang Pharmaceutical Co., Ltd. Corporation Information
 Table 136. Shaanxi Han Tang Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 137. Shaanxi Han Tang Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 138. Shaanxi Han Tang Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 139. Shaanxi Han Tang Pharmaceutical Co., Ltd. Recent Developments
 Table 140. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Corporation Information
 Table 141. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 142. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 143. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 144. Jiangxi Jimin Kexin Pharmaceutical Co., Ltd. Recent Developments
 Table 145. Liaoning Xingao Pharmaceutical Co., Ltd. Corporation Information
 Table 146. Liaoning Xingao Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 147. Liaoning Xingao Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 148. Liaoning Xingao Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 149. Liaoning Xingao Pharmaceutical Co., Ltd. Recent Developments
 Table 150. Hebei Tiancheng Pharmaceutical Co., Ltd. Corporation Information
 Table 151. Hebei Tiancheng Pharmaceutical Co., Ltd. Description and Major Businesses
 Table 152. Hebei Tiancheng Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
 Table 153. Hebei Tiancheng Pharmaceutical Co., Ltd. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 154. Hebei Tiancheng Pharmaceutical Co., Ltd. Recent Developments
 Table 155. Key Raw Materials Distribution
 Table 156. Raw Materials Key Suppliers
 Table 157. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 158. Milestones in Production Technology Evolution
 Table 159. Distributors List
 Table 160. Market Trends and Market Evolution
 Table 161. Market Drivers and Opportunities
 Table 162. Market Challenges, Risks, and Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources


List of Figures
 Figure 1. Anti-inflammatory and Antipyretic Granules Product Picture
 Figure 2. Global Anti-inflammatory and Antipyretic Granules Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Pack of 10 Product Picture
 Figure 4. Pack of 16 Product Picture
 Figure 5. Global Anti-inflammatory and Antipyretic Granules Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Online Sales
 Figure 7. Offline Sales
 Figure 8. Anti-inflammatory and Antipyretic Granules Report Years Considered
 Figure 9. Global Anti-inflammatory and Antipyretic Granules Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 10. Global Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 11. Global Anti-inflammatory and Antipyretic Granules Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 12. Global Anti-inflammatory and Antipyretic Granules Revenue Market Share by Region (2020-2031)
 Figure 13. Global Anti-inflammatory and Antipyretic Granules Sales (2020-2031) & (K Units)
 Figure 14. Global Anti-inflammatory and Antipyretic Granules Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 15. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Region (2020-2031)
 Figure 16. Top 5 and Top 10 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Volume Market Share in 2024
 Figure 17. Global Anti-inflammatory and Antipyretic Granules Revenue Market Share Ranking (2024)
 Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 19. Pack of 10 Revenue Market Share by Manufacturer in 2024
 Figure 20. Pack of 16 Revenue Market Share by Manufacturer in 2024
 Figure 21. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Type (2020-2031)
 Figure 22. Global Anti-inflammatory and Antipyretic Granules Revenue Market Share by Type (2020-2031)
 Figure 23. Global Anti-inflammatory and Antipyretic Granules Sales Market Share by Application (2020-2031)
 Figure 24. Global Anti-inflammatory and Antipyretic Granules Revenue Market Share by Application (2020-2031)
 Figure 25. North America Anti-inflammatory and Antipyretic Granules Sales YoY (2020-2031) & (K Units)
 Figure 26. North America Anti-inflammatory and Antipyretic Granules Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. North America Top 5 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) in 2024
 Figure 28. North America Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Type (2020- 2031)
 Figure 29. North America Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 30. North America Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Application (2020-2031)
 Figure 31. North America Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 32. US Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 33. Canada Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 34. Mexico Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 35. Europe Anti-inflammatory and Antipyretic Granules Sales YoY (2020-2031) & (K Units)
 Figure 36. Europe Anti-inflammatory and Antipyretic Granules Revenue YoY (2020-2031) & (US$ Million)
 Figure 37. Europe Top 5 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) in 2024
 Figure 38. Europe Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Type (2020-2031)
 Figure 39. Europe Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 40. Europe Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Application (2020-2031)
 Figure 41. Europe Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 42. Germany Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 43. France Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 44. U.K. Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 45. Italy Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 46. Russia Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 47. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales YoY (2020-2031) & (K Units)
 Figure 48. Asia-Pacific Anti-inflammatory and Antipyretic Granules Revenue YoY (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Top 8 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) in 2024
 Figure 50. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Type (2020- 2031)
 Figure 51. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 52. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Application (2020-2031)
 Figure 53. Asia-Pacific Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 54. Indonesia Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 55. Japan Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 56. South Korea Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 57. China Taiwan Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 58. India Anti-inflammatory and Antipyretic Granules Revenue (2020-2031) & (US$ Million)
 Figure 59. Central and South America Anti-inflammatory and Antipyretic Granules Sales YoY (2020-2031) & (K Units)
 Figure 60. Central and South America Anti-inflammatory and Antipyretic Granules Revenue YoY (2020-2031) & (US$ Million)
 Figure 61. Central and South America Top 5 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) in 2024
 Figure 62. Central and South America Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Type (2021-2031)
 Figure 63. Central and South America Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 64. Central and South America Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Application (2020-2031)
 Figure 65. Central and South America Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 66. Brazil Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 67. Argentina Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 68. Middle East, and Africa Anti-inflammatory and Antipyretic Granules Sales YoY (2020-2031) & (K Units)
 Figure 69. Middle East and Africa Anti-inflammatory and Antipyretic Granules Revenue YoY (2020-2031) & (US$ Million)
 Figure 70. Middle East and Africa Top 5 Manufacturers Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) in 2024
 Figure 71. Middle East and Africa Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Type (2021-2031)
 Figure 72. South America Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 73. Middle East and Africa Anti-inflammatory and Antipyretic Granules Sales Volume (K Units) by Application (2020-2031)
 Figure 74. Middle East and Africa Anti-inflammatory and Antipyretic Granules Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 75. GCC Countries Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 76. Turkey Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 77. Egypt Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 78. South Africa Anti-inflammatory and Antipyretic Granules Revenue (2020-2025) & (US$ Million)
 Figure 79. Anti-inflammatory and Antipyretic Granules Industry Chain Mapping
 Figure 80. Regional Anti-inflammatory and Antipyretic Granules Manufacturing Base Distribution (%)
 Figure 81. Global Anti-inflammatory and Antipyretic Granules Production Market Share by Region (2020-2031)
 Figure 82. Anti-inflammatory and Antipyretic Granules Production Process
 Figure 83. Regional Anti-inflammatory and Antipyretic Granules Production Cost Structure
 Figure 84. Channels of Distribution (Direct Vs Distribution)
 Figure 85. Bottom-up and Top-down Approaches for This Report
 Figure 86. Data Triangulation
 Figure 87. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Ibuprofen Granules Market Research Report 2024
Global Arginine Ibuprofen Granules Market Research Report 2024
Global Antipyretic Paste Market Research Report 2025
Global Anti Bumping Granules Market Research Report 2024
Global Antibacterial ABS Granule Market Research Report 2024
Global Boiling Granules Market Research Report 2024
Global Anti Inflammatory Gel Market Research Report 2024
Global Anti Inflammatory Tea Market Research Report 2025
Global Acanthopanax Granules Market Research Report 2024
Global Digestive Health Complex Granules Market Research Report 2024
Global Anti Inflammatory and Analgesic Gel Market Research Report 2024
Global Anti inflammatory Eyedrops Market Research Report 2024
Global Antipyretic and Analgesic API Market Research Report 2024
Global Inflammatory POCT Market Research Report 2024
Global Plastic Granules Market Research Report 2024
Antipyretic and Analgesic Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antipyretic Chinese Traditional Medicine Market Insights Forecast to 2030
Global TPU Granules Market Research Report 2025
Global Antigout Agent Market Research Report 2024
Digestive Health Granules Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Levothyroxine Sodium Tablets Hormone Medication Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-25N19924
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Needle Free Allergy Therapy Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24B19783
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Hydrotalcite Antacid Chewable Tablets Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20305
Fri Nov 28 00:00:00 UTC 2025

Add to Cart

Global Dual Orexin Receptor Antagonist Sleeping Pills Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12S20176
Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions